🇺🇸 FDA

Company profile · Sponsor

Axsome

Axsome Therapeutics

AXSM · NYSE pharma NEW YORK, NY, USA
Pipeline
24
Drugs
3
Patents
8

Quick answer

Axsome (AXSM) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

Company facts

Ticker AXSM
Exchange NYSE
Company type pharma
Headquarters NEW YORK, NY, USA
SEC CIK 0001579428

Pipeline (24)

Search pipeline →

  1. AXS-02

    Axsome

    Osteoarthritis, Knee

    phase 3 small molecule active

    1 trial

  2. AXS-02 (oral zoledronate)

    Axsome

    Complex Regional Pain Syndrome

    phase 3 small molecule active

    1 trial

  3. AXS-05

    Axsome

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    3 trials

  4. AXS-05

    Axsome

    Depression

    phase 3 small molecule completed

    1 trial

  5. AXS-05

    Axsome

    Treatment Resistant Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  6. AXS-05 (dextromethorphan and bupropion) oral tablets

    Axsome

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  7. AXS-05 (dextromethorphan-bupropion)

    Axsome

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    2 trials

  8. AXS-07

    Axsome

    Migraine

    phase 3 small molecule completed

    1 trial

  9. AXS-07 (MoSEIC meloxicam and rizatriptan)

    Axsome

    Migraine

    phase 3 small molecule completed

    2 trials

  10. AXS-07 (meloxicam-rizatriptan)

    Axsome

    Migraine

    phase 3 small molecule completed

    1 trial

  11. AXS-12 (Reboxetine)

    Axsome

    Narcolepsy

    phase 3 small molecule completed

    3 trials

  12. AXS-14 (Esreboxetine)

    Axsome

    Fibromyalgia

    phase 3 small molecule active

    1 trial

  13. Solriamfetol 150 MG

    Axsome

    Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

    phase 3 small molecule active

    1 trial

  14. Solriamfetol 150 mg

    Axsome

    Excessive Sleepiness

    phase 3 small molecule active

    1 trial

  15. Solriamfetol 150 mg

    Axsome

    ADHD

    phase 3 small molecule completed

    1 trial

  16. Solriamfetol 150 mg

    Axsome

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial

  17. Solriamfetol 300 mg

    Axsome

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  18. Solriamfetol 75mg, 150 mg, or 300 mg

    Axsome

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial

  19. AXS-05

    Axsome

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  20. AXS-05

    Axsome

    Smoking Cessation

    phase 2 small molecule completed

    1 trial

  21. AXS-05 (dextromethorphan-bupropion)

    Axsome

    Treatment Resistant Depression

    phase 2 small molecule terminated

    1 trial

  22. Dextromethorphan-Bupropion

    Axsome

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

  23. Solriamfetol

    Axsome

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  24. Solriamfetol 150 mg Oral Tablet

    Axsome

    Narcolepsy

    phase 1 small molecule completed

    1 trial

Drugs (3)

Search drugs →

  1. bupropion hydrochloride

    BUPROPION HYDROCHLORIDE

    ORAL approved

  2. meloxicam

    MELOXICAM

    ORAL approved

  3. solriamfetol hydrochloride

    SUNOSI

    ORAL approved

Patents (8)

Search patents →

  1. US 12390419

    Formulations of (R)-2-amino-3-phenylpropyl carbamate

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12384743

    Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12370196

    Pharmaceutical compositions comprising meloxicam

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12357640

    Pharmaceutical compositions comprising meloxicam

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12357697

    Pharmaceutical compositions comprising bupropion and cysteine

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12318362

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12268693

    Pharmaceutical compositions comprising a tolfenamic acid

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12263145

    Methods of administering solriamfetol to lactating women

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Axsome?

Axsome (AXSM) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

What pipeline programs does Axsome sponsor?

We track 24 ClinicalTrials.gov-linked programs for Axsome, including AXS-02 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Axsome company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.